UCB S.A.: PharmaVitae Report

Datamonitor, October 2011, Pages: 82

This analysis examines the historical and forecast performance for UCB in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs

Features and benefits

- Gain insight into UCB's strategic outlook across the next 6 years.
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

Although UCB's prescription sales growth through to 2016 will be impacted by generic erosion of its biggest drug, Keppra, forecast gains associated with uptake of new offerings Cimzia and epratuzumab will drive overall growth and allow an improvement on UCB's historical performance.

Your key questions answered

- Benchmark UCB's performance against key rivals in the prescription pharmaceutical sector
- Assess how successful UCB will be in diversifying its business focus and reducing its reliance on the epilepsy market
- See how UCB proprietary biotechnology platform, gained through the acquisition of Celltech, will support UCB’s expansion in the biologics drug market.

Executive Summary
Key findings
UCB prescription pharma sales outlook
UCB financial outlook
Key developments
[Missing title]
Upcoming developments
Strengths
Weaknesses
Opportunities
Threats
A ABOUT THIS REPORT
PharmaVitae Explorer database
Chapter structure
Strategic insight
Company introduction
Sales analysis
Financial analysis
Product analysis
Data sourcing
Analyst consensus
STRATEGIC INSIGHT
Key findings
Strategic insight
Vimpat will play a crucial role in the near term, as development of Rikelta is delayed
UCB has a shrewd strategy to optimize growth of its leading biological drug
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
Celltech
Schwarz Pharma
Current corporate structure
SALES ANALYSIS
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2004–
Product analysis
Product analysis, 2004–
Product analysis, 2010–
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2010–
Core analysis, 2010–
Expiry analysis, 2010–
Generics analysis, 2010–
Launch/core/expiry configuration, 2010–
Molecule type analysis
Externalization analysis
FINANCIAL ANALYSIS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2004–
Operating costs and profit analysis
Operating costs and profit analysis, 2004–
Operating cost ratio and profit margin analysis, 2004–
Operating cost ratio and profit margin analysis, 2010–
Operating costs and profit analysis, 2010–
PRODUCT ANALYSIS
Overview
Cimzia
Vimpat
Keppra
Neupro
Rikelta
UCB pipeline overview
APPENDIX
References
Abbreviations
Exchange rates

Customers who bought this item also bought

• Generic Defense Strategies: Lifecycle Management Strategies to Maximize Revenue in the Face of Growing Generic Competition
• Sports and Fitness Nutrition - Global Strategic Business Report
• Economic 360 for China: Growth Prospects and Emerging Opportunities in the Aerospace Industry
• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles
• Global Defense Land Vehicle Industry 2012-2017: Trend, Profit, and Forecast Analysis
• WAN Route Towards PSN Connectivity: A Summary of the UK Local Government Wide Area Networking Market
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Comparative SWOT Analysis - World's 5 Leading Armoured Vehicles Manufacturers - Oshkosh Corporation, General Dynamics Land Systems, BAE Systems, Force Protection, Navistar Defense
• Aerospace and Defense Industry - Global Outlook
• The 111th U.S. Congress Tackles Healthcare Reform and the Pharmaceutical Industry